echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Regeneron "cocktail" therapy can effectively protect animals and speed up the elimination of viruses

    Regeneron "cocktail" therapy can effectively protect animals and speed up the elimination of viruses

    • Last Update: 2020-09-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Regeneron's research team has released the latest animal trial results for the prevention and treatment of new coronavirus infections using its anti-new coronavirus (SARS-CoV-2) anti-antibody "cocktail" therapy on preprinted website bioRxiv.
    In this paper, researchers found that REGN-CoV2, in two animal models, Rhesus Monkeys and Golden Hamsters, was able to rapidly improve the virus's removal rate as a preventive therapy, in addition to rapidly increasing the rate of virus removal after an animal be infected with the new coronavirus, as a preventive therapy to improve the protection of animals, significantly speeding up the subsequent virus removal in the test.
    antibodies have long been considered powerful tools by industry experts to improve passive immunity to new coronavirus before an effective vaccine appears.
    Regeneratives has extensive experience in developing meso-antibody therapies for infectious diseases, and its antibody "cocktail" therapy for Ebola virus infection, REGN-EB3, has shown excellent therapeutic results in clinical trials.
    the antibody "cocktail" therapy, called REGN-CoV2, consists of two kinds of meso-antibodies that bind to different bits in the critical bind binding domain (RBD) of the new coronavirus pyroid protein.
    in two papers published in the journal Science on Tuesday, the regenerative team found that biantibodies not only act effectively against a single antibody, but also prevent the virus from developing resistance through mutations under the selected pressure of a single antibody therapy.
    study, researchers further explored the potential of REN-CoV2 to treat and prevent new coronavirus infections in rhesus monkey models.
    for preventive treatment, the researchers injected six rhesus monkeys with a dose of 50 mg/kg of REGN-CoV2, and then tested them for poison three days after the injection.
    results showed that a large number of newly replicated new coronaviruses appeared in nasal swabs and anti-bubble syringe (BAL) samples from six monkeys injected with placebo injections, while REGN-CoV2 almost completely blocked the virus's replication in nasal swab samples and BAL samples, and significantly accelerated the removal of the new coronavirus.
    even though the researchers increased the dose by 10 times, REGN-CoV2 showed good preventive results.
    in a therapeutic trial, researchers injected reGN-CoV2 a day after poisoning the monkeys, and the results showed that animals treated with REGN-CoV2 also improved the speed with which the new coronavirus was removed.
    because the new coronavirus infection in the rhesus monkey model only leads to short-lived viral replication and mild clinical symptoms, the researchers decided to repeat the REGN-CoV2 experiment in the golden hamster model.
    golden hamsters develop very high viral loads in the lungs after contracting the new coronavirus infection, severe lung pathology and rapid weight loss.
    model may better simulate severe COVID-19 patients.
    results showed that in this model, different doses of preventive REVEN-CoV2 injections two days prior to the infection could significantly reverse weight loss due to new coronavirus infections.
    and seven days after the attack, the viral load on the animal's lungs also dropped significantly.
    discussion of the paper, the researchers noted that REGN-CoV2, as a preventive therapy, almost completely blocks replication of the new coronavirus in upper and lower respiratory tract samples in rhesus monkey models.
    shows its potential to prevent new coronavirus infections in addition to treating them.
    two days before the launch, Johnson and Johnson released the results of its experiments in the same rhesus monkey model for Ad26.COV2.S, a new coronavirus vaccine.
    REK-CoV2 as a preventive therapy in controlling the replication of the new coronavirus is comparable to the performance of Ad26.COV2.S.
    In early July, Regeneration announced that REGN-CoV2 had shown good safety characteristics in Phase 1 clinical trials, and that two Phase 3 clinical trials had been launched to evaluate the effectiveness of this medium-antibody "cocktail" therapy in preventing and treating new coronavirus infections.
    ()
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.